Ortho to Present 10 Scientific Posters, Seven Products at AACC

At the 2017 annual meeting of the American Association for Clinical Chemistry, Ortho Clinical Diagnostics, Raritan, NJ, will present 10 scientific posters highlighting its focus on immunodiagnostics, with discussions on acute kidney injury (AKI), insulin, and infectious disease.  At booth 3517, Ortho will display its clinical lab and immunohematology analyzers. The conference will be held July 30 to August 3 at the San Diego Convention Center.

“The abundance of research, product information, and expertise we’re sharing at the AACC meeting reflects the tremendous amount of work Ortho has accomplished over the past year,” says Robert Yates, chief operating officer for Ortho. “Ortho is reimagining the laboratory through the strength of our full testing automation. Our innovative systems and solutions remove distractions and reduce time-consuming turnaround periods, empowering the lab to focus on patient needs.”

Ortho will display the following posters at the conference:

• Performance evaluation of the Vitros Nephrocheck test
  • Poster session: August 1 from 9:30 am to 5 pm
  • Author presentation: 12:30 pm to 1:30 pm
  • Presenter: Godwin Ogbonna, principal scientist, Ortho Clinical Diagnostics

• Performance evaluation of the Vitros immunodiagnostic products insulin test on the Vitros ECi/ECiQ immunodiagnostic systems, Vitros 3600 immunodiagnostic system, and Vitros 5600 integrated system
  • Poster session: August 1 from 9:30 am to 5 pm
  • Author presentation: 12:30 pm to 1:30 pm
  • Presenter: Holly Groth, staff scientist, Ortho Clinical Diagnostics

• An evaluation of performance of the Vitros immunodiagnostic products HIV combo assay
  • Poster session: August 2 from 9:30 am to 5 pm
  • Author presentation: 12:30 pm to 1:30 pm
  • Presenter: Paul Contestable, principal scientist, Ortho Clinical Diagnostics

• Performance of the Prototype HTLV I+II assay
  • Poster session: August 2 from 9:30 am to 5 pm
  • Author presentation: 12:30 pm to 1:30 pm
  • Presenter: Sue Danielson, PhD, senior principal scientist, Ortho Clinical Diagnostics

• Evaluation and performance of a new and novel visible method for the measurement of ALT on Vitros systems
  • Poster session: August 2 from 9:30 am to 5 pm
  • Author presentation: 12:30 pm to 1:30 pm
  • Presenter: Van Thai-Paquette, scientist II, Ortho Clinical Diagnostics

• Development and evaluation of the prototype multitest TRIG-CHOL slides
  • Poster session: August 2 from 9:30 am to 5 pm
  • Author presentation: 12:30 pm to 1:30 pm
  • Presenter: Ted DiMagno, principal scientist, Ortho Clinical Diagnostics

• Performance of the EFK Diagnostics, Stanbio, ?-Hydroxybutyrate LiquiColor assay on the Vitros 4600 chemistry system and the Vitros 5600 integrated system
  • Poster session: August 2 from 9:30 am to 5 pm
  • Author presentation: 12:30 pm to 1:30 pm
  • Presenter: Karen Ackles, scientist II, Ortho Clinical Diagnostics

• Cedia heroin metabolite (6-AM) application for the Ortho Clinical Diagnostics Vitros 4600 chemistry system and Vitros 5600 integrated system
  • Poster session: August 2 from 9:30 am to 5 pm
  • Author presentation: 12:30 pm to 1:30 pm
  • Presenter: Tony Huynh, technical applications specialist II, Thermo Fisher Scientific

• DRI hydrocodone application on the Ortho Clinical Diagnostics Vitros 4600 chemistry system and Vitros 5600 integrated system
  • Poster session: August 2 from 9:30 am to 5 pm
  • Author presentation: 12:30 pm to 1:30 pm
  • Presenter: Tony Huynh, technical applications specialist II, Thermo Fisher Scientific

• DRI methadone metabolite (EDDP) application on the Ortho Clinical Diagnostics Vitros 4600 chemistry system and Vitros 5600 integrated system
  • Poster session: August 2 from 9:30 am to 5 pm
  • Author presentation: 12:30 pm to 1:30 pm
  • Presenter: Michael Aquino, lead, senior scientist, Thermo Fisher Scientific

Products on display in Ortho’s booth will include Vitros 3600 immunodiagnostic systems, Vitros 4600 chemistry systems, Vitros 5600 integrated systems, Vitros automation solutions, and the Ortho Vision and Ortho Vision Max analyzers. Ortho will also highlight the Nephrocheck test, a risk assessment tool for predicting AKI. The test is currently in development, and not approved or cleared in the United States.

“AACC is a wonderful opportunity for us to engage with members of the lab community and hear their feedback on our products, both current and in development,” says Alex Socárras, chief commercial officer for Ortho.

For more information, visit Ortho.